Navigation Links
1 in 10 advanced colon cancer patients worry about prescription drug costs
Date:5/29/2009

ORLANDO, Fla.--The vast majority of advanced colon cancer patients in a clinical trial were not concerned about the cost of prescription drugs for managing chemotherapy side effects, such as infection, pain and nausea and few adopted strategies to reduce drug cost burdens after joining the clinical trial, according to a study led by researchers at Dana-Farber Cancer Institute in Boston. Although few patients reported substantial worry about drug costs, still fewer reported discussing drug cost issues with their physicians, suggesting there are opportunities for improving how physicians integrate discussions about drug costs into clinical practice.

The study's findings (abstract 9503) will be presented at the American Society of Clinical Oncology's annual meeting in Orlando, Fla. on Friday, May 29, 5:30 pm ET, Level 4, W414A.

"We were reassured to learn that few patients enrolled in the clinical trial engaged in coping strategies to minimize the impact of prescription drug costs, but we also recognize that these findings may not generalize to patients treated outside the clinical trial context," said the study's lead author, Deborah Schrag, MD, MPH, of Dana-Farber.

Schrag added that given the current state of the economy, with a growing number of people losing their jobs and possibly some or all of their insurance coverage, "we could witness growing anxiety among cancer patients about their ability to pay for medications that may help them adhere to their therapy."

The researchers surveyed 409 patients with metastatic colorectal cancer who were enrolled in a Cancer Leukemia Group B (CALGB) Phase III clinical trial that compared outcomes of patients who received combination chemotherapy in conjunction with bevacizumab and cetuximab together or with cetuximab alone. The participants also received prescriptions for "supportive" drugs, such as anti-nausea medications, antibiotics and painkillers.

They explored whether financial concerns prompted the patients to take money-saving steps that could negatively impact their care. They found that 10 percent of the patients were very worried about paying for their supportive medications, less than 15 percent adopted a money-saving strategy -- such as not filling a prescription, taking less than the recommended dose -- and 12 percent of the patients reported speaking with their physicians about drug costs.

"The cost of cancer care today does force patients to make some hard financial decisions," said Schrag. "As oncologists, we need to be mindful that this issue may be a concern for some patients and that communication about this topic both may help alleviate anxiety and identify strategies to minimize the cost burden."


'/>"/>

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
440-670-6563
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. One in ten advanced colon cancer patients worry about prescription drug costs
2. Advanced Life Sciences Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Restanza(TM) (cethromycin)
3. More Living Longer With Advanced Colon Cancer
4. Advanced Technologies Pump Growth Into European Cardiac Rhythm Management Market, Affirms Frost & Sullivan
5. Advanced Prostate Cancer Deadlier in Younger Men
6. Younger men with advanced prostate cancer have shorter survival times
7. African-American women with advanced breast cancer often forego vital treatment
8. Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
9. Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
10. SETO Holdings, Inc. Signs Agreement to Acquire Advanced Hearing Centers, Inc. and Will Dispose of All Existing Business; New Management to be Installed
11. Frost & Sullivan: Clinical and Cost Benefits to Promote Uptake of Advanced Wound Management Technologies Across Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Ten outstanding teachers in the Greater Houston area ... will win a visit by a Houston Texans player, two tickets to a Texans ... years old can visit texanschecking.com/stars to nominate their favorite teacher with an essay of ...
(Date:8/16/2017)... Georgia (PRWEB) , ... August 16, 2017 , ... ... in Atlanta, opened their doors. They celebrate 30 years in business this year, ... create an up-to-date, inviting, tranquil space to serve their patients. , It ...
(Date:8/16/2017)... ... August 16, 2017 , ... Maury Regional Health has announced ... draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is making vein visualization ... out of a needle stick and more importantly, helps our staff members locate a ...
(Date:8/16/2017)... ... 2017 , ... A global leader in the treatment of clubfoot, CURE ... Indian states—bringing the country one step closer to eliminating clubfoot as a lifelong disability ... on track to enroll 10,000 children in the clubfoot treatment program in this year ...
(Date:8/16/2017)... ... ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has announced their ... a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their content will ... in 2018. Proceeds will be going to further health research. , Fusion Flix ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... -- Axium Pharmaceuticals Inc., the creator of the drug Truveta for ... of an IPO. The United States ... of a prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... staggering figure is the fact that Americans spent $42 billion on anxiety ...
(Date:8/14/2017)... Israel , Aug. 15, 2017  BrainStorm ... adult stem cell technologies for neurodegenerative diseases, announced financial ... "We are in ... 3 trial to investigate NurOwn ® in ALS," ... Officer of BrainStorm. "We have agreements with Mass. General ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
Breaking Medicine Technology: